Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition.

2.50
Hdl Handle:
http://hdl.handle.net/10146/78093
Title:
Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition.
Authors:
Nimptsch, Katharina; Rohrmann, Sabine; Nieters, Alexandra; Linseisen, Jakob
Abstract:
From cell studies, Vitamin K is known to exert anticancer effects on a variety of cancer cell lines, including prostate cancer cells. Recently, we reported an inverse association between dietary intake of menaquinones (vitamin K(2)), but not phylloquinone (vitamin K(1)), and risk of prostate cancer. In this nested case-control study including 250 prostate cancer cases and 494 matched controls, we aimed to confirm this cancer-protective effect using serum undercarboxylated osteocalcin (ucOC), a biomarker of vitamin K status inversely associated with vitamin K intake. In addition, effect modification by a functionally relevant polymorphism in the vitamin K epoxide reductase gene (VKORC1) was assessed. Serum ucOC and intact total osteocalcin (iOC) were analyzed with the use of ELISA tests. Serum ucOC was expressed relative to iOC (i.e., as ucOC/iOC ratio). Conditional logistic regression was used to calculate multivariate adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Serum ucOC/iOC ratio was positively associated with advanced-stage (OR per 0.1 increment, 1.38; 95% CI, 1.03-1.86) and high-grade prostate cancer (OR, 1.21; 95% CI, 1.00-1.46) but not with total prostate cancer. The significant association with advanced-stage prostate cancer was confirmed when serum ucOC/iOC ratio was jointly modeled with menaquinone intake data. There was indication of a lower prostate cancer risk in carriers of the A allele (compared with GG carriers) of the +2255 VKORC1 polymorphism with increasing menaquinone intake (P(interaction) = 0.14) whereas no distinct effect modification was observed for the ucOC/iOC ratio (P(interaction) = 0.37). The increased risks of advanced-stage and high-grade prostate cancer with higher serum ucOC/iOC ratio strengthen the findings for dietary menaquinone intake.
Citation:
Cancer Epidemiol. Biomarkers Prev. 2009, 18 (1):49-56
Journal:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Issue Date:
Jan-2009
URI:
http://hdl.handle.net/10146/78093
DOI:
10.1158/1055-9965.EPI-08-0554
PubMed ID:
19124480
Additional Links:
http://cebp.aacrjournals.org/cgi/content/abstract/18/1/49
Type:
Article
Language:
en
ISSN:
1055-9965
Appears in Collections:
Articles

Full metadata record

DC FieldValue Language
dc.contributor.authorNimptsch, Katharina-
dc.contributor.authorRohrmann, Sabine-
dc.contributor.authorNieters, Alexandra-
dc.contributor.authorLinseisen, Jakob-
dc.date.accessioned2009-08-21T08:43:09Z-
dc.date.available2009-08-21T08:43:09Z-
dc.date.issued2009-01-
dc.identifier.citationCancer Epidemiol. Biomarkers Prev. 2009, 18 (1):49-56en
dc.identifier.issn1055-9965-
dc.identifier.pmid19124480-
dc.identifier.doi10.1158/1055-9965.EPI-08-0554-
dc.identifier.urihttp://hdl.handle.net/10146/78093-
dc.description.abstractFrom cell studies, Vitamin K is known to exert anticancer effects on a variety of cancer cell lines, including prostate cancer cells. Recently, we reported an inverse association between dietary intake of menaquinones (vitamin K(2)), but not phylloquinone (vitamin K(1)), and risk of prostate cancer. In this nested case-control study including 250 prostate cancer cases and 494 matched controls, we aimed to confirm this cancer-protective effect using serum undercarboxylated osteocalcin (ucOC), a biomarker of vitamin K status inversely associated with vitamin K intake. In addition, effect modification by a functionally relevant polymorphism in the vitamin K epoxide reductase gene (VKORC1) was assessed. Serum ucOC and intact total osteocalcin (iOC) were analyzed with the use of ELISA tests. Serum ucOC was expressed relative to iOC (i.e., as ucOC/iOC ratio). Conditional logistic regression was used to calculate multivariate adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Serum ucOC/iOC ratio was positively associated with advanced-stage (OR per 0.1 increment, 1.38; 95% CI, 1.03-1.86) and high-grade prostate cancer (OR, 1.21; 95% CI, 1.00-1.46) but not with total prostate cancer. The significant association with advanced-stage prostate cancer was confirmed when serum ucOC/iOC ratio was jointly modeled with menaquinone intake data. There was indication of a lower prostate cancer risk in carriers of the A allele (compared with GG carriers) of the +2255 VKORC1 polymorphism with increasing menaquinone intake (P(interaction) = 0.14) whereas no distinct effect modification was observed for the ucOC/iOC ratio (P(interaction) = 0.37). The increased risks of advanced-stage and high-grade prostate cancer with higher serum ucOC/iOC ratio strengthen the findings for dietary menaquinone intake.en
dc.language.isoenen
dc.relation.urlhttp://cebp.aacrjournals.org/cgi/content/abstract/18/1/49en
dc.subjectBiological Markersen
dc.subjectEnzyme-Linked Immunosorbent Assayen
dc.subjectGenotypeen
dc.subjectMixed Function Oxygenasesen
dc.subjectOsteocalcinen
dc.subjectPolymorphism, Geneticen
dc.subjectProstatic Neoplasmsen
dc.subjectVitamin K 1en
dc.subjectVitamin K 2en
dc.subject.meshAdult-
dc.subject.meshBiological Markers-
dc.subject.meshCase-Control Studies-
dc.subject.meshChi-Square Distribution-
dc.subject.meshEnzyme-Linked Immunosorbent Assay-
dc.subject.meshEurope-
dc.subject.meshGenotype-
dc.subject.meshGermany-
dc.subject.meshHumans-
dc.subject.meshLogistic Models-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMixed Function Oxygenases-
dc.subject.meshOsteocalcin-
dc.subject.meshPolymorphism, Genetic-
dc.subject.meshProspective Studies-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshQuestionnaires-
dc.subject.meshRisk Factors-
dc.subject.meshVitamin K 1-
dc.subject.meshVitamin K 2-
dc.titleSerum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition.en
dc.typeArticleen
dc.identifier.journalCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncologyen

Related articles on PubMed

All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.